{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2130","upperLimit":"8630","value":"4740"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Area under the plasma concentration time curve over the dosing interval tau (ng\\*h/mL), calculated by linear up/log down trapezoidal summation. Calculated for the C1D1 dose only. Actual elapsed sampling time at tau and the corresponding plasma concentration was used in the calculation of this parameter. If concentrations fall to BLQ before or at tau, AUCall (area under the plasma concentration time curve from zero \\[predose\\] to the time of the last observation within the dosing interval, calculated by linear up/log down trapezoidal summation) was used as the estimate of this parameter.","dispersionType":"Full Range","groups":[{"description":"PK Sampling C1D1","id":"OG000","title":"C1D1"}],"paramType":"MEDIAN","populationDescription":"PK population includes all subjects, at the selected sites in Japan and all sites in South Korea, who have pretreatment baseline and at least 1 blood sample on study providing PK data for HBI-8000.","reportingStatus":"POSTED","timeFrame":"0 (predose) up to 72 hours postdose on C1D1","title":"Pharmacokinetics AUC (0-tau)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"ng*h/mL"}